Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

New England Journal of Medicine

Volumn 349, Issue 4, 2003, Pages 350-357

  Sinha, Atul ^a   Nightingale, Jeremy ^a   West, Kevin P ^a   Berlanga Acosta, Jorge ^b   Playford, Raymond J ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ENEMA; MESALAZINE; PLACEBO; PREDNISOLONE; RECOMBINANT EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; REMISSION; SCORING SYSTEM; SIGMOIDOSCOPY; TREATMENT OUTCOME; ULCERATIVE COLITIS; DRUG COMBINATION; FEMALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENEMA; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROCTITIS; REMISSION INDUCTION;

EID: 0037483705     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa013136     Document Type: Article

References (31)

1. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993;342:412-7.
2. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40.
3. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
4. Heitz PU, Kasper M, van Noorden S, Polak JM, Gregory H, Pearse AG. Immunohistochemical localisation of urogastrone to human duodenal and submandibular glands. Gut 1978;19:408-13.
5. Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut 1995;37:595-7.
6. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989;321:76-9.
7. Sullivan PB, Brueton MJ, Tabara ZB, Goodlad RA, Lee CY, Wright NA. Epidermal growth factor in necrotising enteritis. Lancet 1991;338:53-4.
8. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-7.
9. Calnan DP, Fagbemi A, Berlanga-Acosta J, et al. Potency and stability of C terminal truncated human epidermal growth factor. Gut 2000;47:622-7.
10. Chinery R, Playford RJ. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci (Lond) 1995;88:401-3.
11. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
12. Sinha A, Nightingale J, West KP. A simple method of grading the activity of ulcerative colitis using patient symptoms. Gastroenterology 2000;118:Suppl 2:A316. abstract.
13. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Brit Med J 1964;1:89-92.
14. Meyers S, Janowitz HD. The "natural history" of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol 1989;11:33-7.
15. Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000;56:353-62.
16. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
17. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment ofdistal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71.
18. Bell GI, Fong NM, Stempien MM, et al. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res 1986;14:8427-46.
19. Araki F, Nakamura H, Nojima N, Tsukumo K, Sakamoto S. Stability of recombinant human epidermal growth factor in various solutions. Chem Pharm Bull (Tokyo) 1989;37:404-6.
20. Playford RJ, Marchbank T, Calnan DP, et al. Epidermal growth factor is digested to smaller, less active forms in acidic gastric juice. Gastroenterology 1995;108:92-101.
21. Playford RJ, Woodman AC, Clark P, et al. Effect of luminal growth factor preservation on intestinal growth. Lancet 1993;341:843-8.
22. Kelly SM, Jenner JR, Dickinson RJ, Hunter JO. Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion. Gut 1994;35:611-4.
23. Itoh M, Imai S, Joh T, et al. Protection of gastric mucosa against ethanol-induced injury by intragastric bolus administration of epidermal growth factor combined with hydroxypropylcellulose. J Clin Gastroenterol 1992;14:Suppl 1:S127-S130.
24. Berlanga J, Prats P, Remirez D, et al. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am J Pathol 2002;16:373-9.
25. Procaccino F, Reinshagen M, Hoffmann P, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994;107:12-7.
26. Playford RJ, Hanby AM, Gschmeissner S, Peiffer LP, Wright NA, McGarrity T. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surfaces of enterocytes in the human gastrointestinal tract. Gut 1996;39:262-6.
27. Hoffmann P, Reinshagen M, Zeeh JM, et al. Increased expression of epidermal growth factor-receptor in an experimental model of colitis in rats. Scand J Gastroenterol 2000;35:1174-80.
28. Wright NA, Poulsom R, Stamp F, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993;104:12-20.
29. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995;376:337-41.
30. Playford RJ. Recombinant peptides for gastrointestinal ulceration: still early days. Gut 1997;40:286-7.
31. Drumm B, Cutz E, Tomkins KB, Cook D, Hamilton JR, Sherman P. Urogastrone/epidermal growth factor in treatment of congenital microvillous atrophy. Lancet 1988;1:111-2.